As Amgen Drops Some ESA “Overhangs,” New Payment Threat Appears
Executive Summary
Amgen could be facing a new threat on the reimbursement front just days after celebrating the removal of several "major overhangs" to its erythropoiesis-stimulating agents during its second quarter earnings call
You may also be interested in...
ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress
Erythropoiesis-stimulating agents marketed by Amgen and Johnson & Johnson now confront possible restrictions on use in patients with anemia due to chronic kidney disease, as FDA and CMS gear up for separate advisory panel reviews of emerging safety data on such treatment
ESAs In Renal Use May Face New FDA, CMS Constraints; REMS Still In Progress
Erythropoiesis-stimulating agents marketed by Amgen and Johnson & Johnson now confront possible restrictions on use in patients with anemia due to chronic kidney disease, as FDA and CMS gear up for separate advisory panel reviews of emerging safety data on such treatment
MedCAC To Examine ESAs In Chronic Kidney Disease, Pharmacogenomic Testing In Cancer
The usage of erythropoiesis stimulating agents outside the renal setting is already subject to coverage limitations in Medicare.